XPO1 and glioblastoma: Research showed that SINE compounds, such as the first-generation XPO1 inhibitor Selinexor (KPT-802), approved by the FDA for multiple myeloma therapy can induce apoptosis in GBM cells and respective animal models without overt evidence of neurotoxicity [49,50].